CONNAXIS SERVICIOS DE MARKETING SL

Their core work

CONNAXIS is a Madrid-based marketing consultancy that applies commercial marketing methodologies to public health challenges — specifically improving how communities adopt health protocols, screening programs, and vaccination campaigns. Their work centers on designing tailored communication strategies and behavioral interventions that reach underserved or hard-to-engage populations. In EU research consortia, they contribute the demand-side perspective: how to make scientifically sound health protocols actually get used by real people in real communities. They bring participatory research methods and equity-focused outreach design to projects where clinical teams solve the "what works" question and CONNAXIS solves the "how do we get people to do it" question.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2021, so there is no true temporal gap to track — but the keyword split between the two projects reveals a meaningful thematic breadth. The earlier project (PRESCRIP-TEC) sits in disease-specific territory: cervical cancer screening, HPV-test protocols, AI-assisted detection, and cost-effectiveness analysis — a focused clinical-program communication challenge. The second project (RIVER-EU) broadens significantly toward population-level health equity: vaccine hesitancy, multiple disease areas (MMR, HPV), adolescent health, and participatory action research with marginalized groups. The direction of travel is clear: from single-disease protocol promotion toward systemic health equity communication, which is a higher-complexity and more strategically valuable positioning.

CONNAXIS is moving from narrow disease-area communication toward broad health equity and vaccine hesitancy work, which positions them well for the growing EU policy focus on health inequalities and immunization gaps.

How they like to work

CONNAXIS has never led an H2020 project — both participations are as consortium partner, which is consistent with a specialist firm brought in for a specific non-clinical capability. They operate inside large consortia: 31 unique partners across 12 countries from just 2 projects suggests each consortium is substantial (approximately 15+ partners each). This profile indicates a reliable specialist contributor rather than a consortium builder — organizations looking for a communication or social marketing partner in a health project would invite them in; they would not typically initiate the bid.

CONNAXIS has built a network of 31 unique partners across 12 countries through only 2 projects, suggesting deep embeddedness in large, geographically diverse health research consortia. Their reach is pan-European, with no apparent geographic clustering, which reflects the multi-country design typical of RIA health equity studies.

What sets them apart

CONNAXIS occupies an unusual niche: a private marketing company that operates inside rigorous public health research consortia, bridging the gap between scientific evidence and community-level adoption. Most health research consortia lack internal marketing expertise, making a firm like CONNAXIS valuable precisely because it is not a university or NGO — it brings commercial-grade communication design, audience segmentation, and behavior change frameworks that academic partners cannot replicate. Their focus on equity and underserved populations adds a social dimension that strengthens consortium grant applications under Horizon Europe's inclusion agenda.

Highlights from their portfolio

• PRESCRIP-TEC
  Largest single funding award (EUR 222,500) and notable for combining AI-assisted screening protocols with community-based outreach — an unusual pairing that required both technical and communication partners.
• RIVER-EU
  Longest project duration (2021-2026) and broadest scope, addressing vaccine inequalities across the entire European region with participatory action research — a flagship EU health equity initiative.